The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 84, positioning it in the top 34% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metr ...

Nvidia (NASDAQ:NVDA) has become the face of artificial intelligence and its stock has responded in kind. Shares are up 200% over the past year and over 800% since the release of ChatGPT, which sparked an AI tsunami. Yet there is a world of stocks that are outperforming Nvidia. While the technology sector provides opportunity with companies like Super Micro Computer (NASDAQ:SMCI) far outstripping the chipmaker's gains, investors should widen their lens even further. Vital Farms (VITL) Source: Poravute Siriph ...

What a difference a few months make. Vaccine specialist Novavax (NVAX -1.32%) started the year poorly, continuing with the issues it has encountered since mid-2021. However, several developments have jolted Novavax's stock since January. The company's shares are up by just under 200% this year. Can it keep up that momentum through the next 12 months? Let's find out. Novavax faced significant uncertainty entering the year, but a recent partnership with Sanofi (SNY 0.92%), a much larger biotech, helped dispel ...

The the stock of vaccine maker has fallen by 15.87% in the past month, lagging the Medical sector's gain of 1.74% and the S&P 500's gain of 3.53%. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-a ...

Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ:NVAX) the green light to target a specific Covid-19 variant. Yet, it's too late to buy Novavax stock with confidence as meme-stock madness sent the share price to the moon already. I'll bet you never imagined that there would be a connection between GameStop (NYSE:GME) and Novavax. Yet, in these bizarre times, there's actually a link between ...

Novavax (NVAX) filed a regulatory application to the EMA, which seeks to update its protein-based COVID19 vaccine for the 2024/2025 vaccination campaign. This submission is in line with the EMA's guidance issued on Apr 30, which advised COVID-19 vaccine manufacturers like Moderna (MRNA) , Novavax, and Pfizer (PFE) to update their respective COVID-19 vaccines to target the JN.1 variant. Year to date, the stock has skyrocketed 192.1% against the industry's 4.1% fall. Image Source: Zacks Investment Research Un ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Revisions to Earnings Estimates For the current quarter, Novavax is expected to post earnings of $1.13 per share, indicating a change of +94.8% from the year-ago quarter. The Zacks Consensus Estimate has changed +544.9% over the last 30 days. With an impressive externally audited track record, our prop ...

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax intends to have its vaccine in unit-dose vials available for distribution in the European Union for immediate release post-approval. Novavax has also filed with the U.S. Food and Drug Administration (FDA) and is working with other regulatory authorities globally on authorization or approval of its JN.1 COVID-19 vaccine. When added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enha ...

Heading into today, shares of the vaccine maker had lost 12.2% over the past month, lagging the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59% in that time. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Novavax (NVAX) closed the most recent trading d ...

It was not long ago that Novavax (NASDAQ:NVAX) was among the stocks with high short interest. The stock had been trending lower for an extended period. However, with one positive news, NVAX stock skyrocketed from February lows of $3.5 to 52-week high of $23.86. This is just one example of short-squeeze stocks delivering multi-fold returns in quick time. In the meme euphoria of 2021, stocks with high short interest as a percentage of free-float was targeted by retail investors. With the meme stock frenzy on ...